Phase II proof-of-concept trial of the orexin receptor antagonist filorexant (MK-6096) in patients with major depressive disorder

Kathryn M. Connor, Paulette Ceesay, Jill Hutzelmann, Duane Snavely, Andrew D. Krystal, Madhukar H. Trivedi, Michael Thase, Christopher Lines, W. Joseph Herring, David Michelson

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)613-618
Number of pages6
JournalInternational Journal of Neuropsychopharmacology
Volume20
Issue number8
DOIs
StatePublished - Aug 1 2017
Externally publishedYes

ASJC Scopus Subject Areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Keywords

  • Depression
  • Filorexant
  • Mk-6096
  • Orexin receptor antagonist

Cite this